NADPH oxidase-IN-1

NADPH oxidase-IN-1 is an orally active NADPH oxidase (Nox) inhibitor, related with neuronal inflammation. NADPH oxidase-IN-1 can cross the blood-brain barrier (BBB), inhibits Nox2 and Nox4 with IC50s of 1.9 μM and 2.47 μM, respectively. NADPH oxidase-IN-1 suppresses pro-inflammatory cytokines production and LPS-mediated microglial migration, also has in vivo efficacy[1].

Product Specifications

CAS Number

[2762405-17-2]

UNSPSC

12352005

Target

NADPH Oxidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/nadph-oxidase-in-1.html

Purity

99.69

Solubility

DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CN(C1=CC=C(C=C1)/C=C2C(N(C(N\2C)=S)C3CCCCC3)=O)CCO

Molecular Formula

C20H27N3O2S

Molecular Weight

373.51

References & Citations

[1]Shim S, et al. Discovery of a NADPH oxidase inhibitor, (E) -3-cyclohexyl-5- (4- ((2-hydroxyethyl) (methyl) amino) benzylidene) -1-methyl-2-thioxoimidazolidin-4-oneone, as a novel therapeutic for Parkinson's disease[J]. European Journal of Medicinal Chemistry, 2022, 244: 114854.